Cover Image
市場調查報告書

胃癌:開發中產品分析

Gastric Cancer - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 232773
出版日期 內容資訊 英文 1283 Pages
訂單完成後即時交付
價格
Back to Top
胃癌:開發中產品分析 Gastric Cancer - Pipeline Review, H1 2018
出版日期: 2018年04月30日 內容資訊: 英文 1283 Pages
簡介

胃癌是胃內膜發生的惡性腫瘤,其徵兆及症狀有倦怠感,腹痛,嘔吐,體重減少,飯後的飽漲感,胃部發熱,消化不良等。罹患胃癌的原因有抽煙、惡性貧血、胃部息肉、感染胃幽門桿菌,家族病史等。

本報告提供胃癌治療藥的開發中產品概要和臨床實驗的各階段產品概要,提供您主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

胃癌 - 概要

胃癌 - 治療藥的開發

胃癌 - 治療藥的評估

胃癌的治療藥開發企業

藥物簡介

胃癌 - 暫停中的計劃

胃癌 - 開發中止的產品

胃癌 - 產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10355IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H1 2018, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 14, 80, 99, 11, 97, 17 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 9, 3, 1, 9 and 2 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • Introduction 9
  • Gastric Cancer - Overview 10
  • Gastric Cancer - Therapeutics Development 11
  • Gastric Cancer - Therapeutics Assessment 47
  • Gastric Cancer - Companies Involved in Therapeutics Development 67
  • Gastric Cancer - Drug Profiles 142
  • Gastric Cancer - Dormant Projects 1226
  • Gastric Cancer - Discontinued Products 1236
  • Gastric Cancer - Product Development Milestones 1239
  • Appendix 1250

List of Tables

  • Table 1: Number of Products under Development for Gastric Cancer, H1 2018 43
  • Table 2: Number of Products under Development by Companies, H1 2018 45
  • Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018 46
  • Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018 47
  • Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018 48
  • Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018 49
  • Table 7: Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018 50
  • Table 8: Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018 51
  • Table 9: Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018 52
  • Table 10: Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018 53
  • Table 11: Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018 54
  • Table 12: Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018 55
  • Table 13: Number of Products under Development by Universities/Institutes, H1 2018 56
  • Table 14: Products under Development by Companies, H1 2018 58
  • Table 15: Products under Development by Companies, H1 2018 (Contd..1), H1 2018 59
  • Table 16: Products under Development by Companies, H1 2018 (Contd..2), H1 2018 60
  • Table 17: Products under Development by Companies, H1 2018 (Contd..3), H1 2018 61
  • Table 18: Products under Development by Companies, H1 2018 (Contd..4), H1 2018 62
  • Table 19: Products under Development by Companies, H1 2018 (Contd..5), H1 2018 63
  • Table 20: Products under Development by Companies, H1 2018 (Contd..6), H1 2018 64
  • Table 21: Products under Development by Companies, H1 2018 (Contd..7), H1 2018 65
  • Table 22: Products under Development by Companies, H1 2018 (Contd..8), H1 2018 66
  • Table 23: Products under Development by Companies, H1 2018 (Contd..9), H1 2018 67
  • Table 24: Products under Development by Companies, H1 2018 (Contd..10), H1 2018 68
  • Table 25: Products under Development by Companies, H1 2018 (Contd..11), H1 2018 69
  • Table 26: Products under Development by Companies, H1 2018 (Contd..12), H1 2018 70
  • Table 27: Products under Development by Companies, H1 2018 (Contd..13), H1 2018 71
  • Table 28: Products under Development by Companies, H1 2018 (Contd..14), H1 2018 72
  • Table 29: Products under Development by Companies, H1 2018 (Contd..15), H1 2018 73
  • Table 30: Products under Development by Companies, H1 2018 (Contd..16), H1 2018 74
  • Table 31: Products under Development by Companies, H1 2018 (Contd..17), H1 2018 75
  • Table 32: Products under Development by Companies, H1 2018 (Contd..18), H1 2018 76
  • Table 33: Products under Development by Universities/Institutes, H1 2018 77
  • Table 34: Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018 78
  • Table 35: Number of Products by Stage and Target, H1 2018 80
  • Table 36: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018 81
  • Table 37: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018 82
  • Table 38: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018 83
  • Table 39: Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018 84
  • Table 40: Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018 85
  • Table 41: Number of Products by Stage and Target, H1 2018 (Contd..6), H1 2018 86
  • Table 42: Number of Products by Stage and Mechanism of Action, H1 2018 88
  • Table 43: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018 89
  • Table 44: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018 90
  • Table 45: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018 91
  • Table 46: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018 92
  • Table 47: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018 93
  • Table 48: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..6), H1 2018 94
  • Table 49: Number of Products by Stage and Route of Administration, H1 2018 96
  • Table 50: Number of Products by Stage and Molecule Type, H1 2018 98
  • Table 51: Gastric Cancer - Pipeline by 3SBio Inc, H1 2018 99
  • Table 52: Gastric Cancer - Pipeline by AbbVie Inc, H1 2018 100
  • Table 53: Gastric Cancer - Pipeline by AbGenomics International Inc, H1 2018 100
  • Table 54: Gastric Cancer - Pipeline by Abion Inc, H1 2018 100
  • Table 55: Gastric Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018 101
  • Table 56: Gastric Cancer - Pipeline by ADC Therapeutics SA, H1 2018 101
  • Table 57: Gastric Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018 102
  • Table 58: Gastric Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018 102
  • Table 59: Gastric Cancer - Pipeline by Alteogen Inc, H1 2018 102
  • Table 60: Gastric Cancer - Pipeline by Ambrx Inc, H1 2018 103
  • Table 61: Gastric Cancer - Pipeline by amcure GmbH, H1 2018 103
  • Table 62: Gastric Cancer - Pipeline by Amgen Inc, H1 2018 104
  • Table 63: Gastric Cancer - Pipeline by ANP Technologies Inc, H1 2018 104
  • Table 64: Gastric Cancer - Pipeline by Antikor Biopharma Ltd, H1 2018 104
  • Table 65: Gastric Cancer - Pipeline by arGEN-X BV, H1 2018 105
  • Table 66: Gastric Cancer - Pipeline by Array BioPharma Inc, H1 2018 105
  • Table 67: Gastric Cancer - Pipeline by Asana BioSciences LLC, H1 2018 106
  • Table 68: Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018 106
  • Table 69: Gastric Cancer - Pipeline by Astellas Pharma Inc, H1 2018 107
  • Table 70: Gastric Cancer - Pipeline by AstraZeneca Plc, H1 2018 107
  • Table 71: Gastric Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2018 108
  • Table 72: Gastric Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018 108
  • Table 73: Gastric Cancer - Pipeline by Avipep Pty Ltd, H1 2018 108
  • Table 74: Gastric Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2018 109

List of Figures

  • Figure 1: Number of Products under Development for Gastric Cancer, H1 2018 43
  • Figure 2: Number of Products under Development by Companies, H1 2018 44
  • Figure 3: Number of Products under Development by Universities/Institutes, H1 2018 56
  • Figure 4: Number of Products by Top 10 Targets, H1 2018 79
  • Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018 79
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018 87
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018 87
  • Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018 95
  • Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018 95
  • Figure 10: Number of Products by Top 10 Molecule Types, H1 2018 97
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018 97
Back to Top